Updated: 5 days ago
Welcome to Cannabis Conclusions, a unique educational series from Higher Learning LV that is targeted at hemp and cannabis industry professionals. This series provides readers with the conclusion section from important modern peer-reviewed research studies.
A January 2022 study entitled "In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties" that was published in the journal Molecules explored various medicinal characteristics of the pivotal cannabinoid CBG.
The scientists stated their goal as "to characterize and compare the in vitro activity profile of non-psychoactive CBG and CBD in skin and be the first group to test CBG clinically on human skin."
"We demonstrate here for the first time that CBG in a clinical study is both safe and effective in promoting skin health by reducing the appearance of redness and improving barrier function better than a placebo.
CBG molecular structure
"CBG exhibits a broad range of in vitro activity, including antioxidant, anti-inflammatory, anti-acne, and anti-aging properties. Based on the data reported here, CBG is an attractive new candidate for dermatological use, outperforming its more well-known derivative, CBD.
"CBG is an attractive new candidate for dermatological use, outperforming its more well-known derivative, CBD."
"Lastly, utilizing our novel yeast fermentation technology platform, we can produce CBG and other minor cannabinoids with higher purity using a more sustainable and cost-effective process compared to C. sativa plant extraction and chemical synthesis."
View the original study.
Like what you just read? Check out our new Cannabis for Cancer Hub that features links to all of our articles about marijuana for cancer.